Stock 000627 HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hubei Biocause Pharmaceutical Co., Ltd.

Equities

000627

CNE000000F48

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 21/06/2024 am IST 		5-day change 1st Jan Change
1.85 CNY +0.54% Intraday chart for Hubei Biocause Pharmaceutical Co., Ltd. -1.60% -34.86%
17/06 Biocause Pharma Plans Buyback of Up to 100 Million Yuan Shares MT
29/04 Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Biocause Pharma Plans Buyback of Up to 100 Million Yuan Shares
MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023
MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.
CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period
MT
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period
MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023
CI
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income
MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022
CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%
MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake
MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022
CI
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 000627 Stock
  4. News Hubei Biocause Pharmaceutical Co., Ltd.